Why the study?
Do ACE inhibitors improve outcomes in patients with heart failure or after myocardial infarction?
Do ACE inhibitors improve outcomes in patients with heart failure or after myocardial infarction?
This review summarizes the established role and mechanisms of ACE inhibitors in managing hypertension, heart failure, and post-myocardial infarction.
Review affirms ACE inhibitor benefits in HF and post-MI; leaves open resolution of recent controversies.
Angiotensin-converting enzyme (ACE) inhibitors were introduced in the early 1980s as a novel class of agents to treat hypertension. Since that time, they have been proven to be a powerful tool in the treatment of symptomatic left ventricular systolic dysfunction. In this article we will summarize the results from clinical trials using ACE inhibitors in the treatment of heart failure and after myocardial infarction. We will discuss some of the mechanisms postulated to account for the beneficial effects associated with ACE inhibitor treatment. Finally, we will highlight some recent controversies in the use of ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Lombardi et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: